These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30420613)

  • 1. SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.
    Yuan X; Li J; Coulouarn C; Lin T; Sulpice L; Bergeat D; De La Torre C; Liebe R; Gretz N; Ebert MPA; Dooley S; Weng HL
    Br J Cancer; 2018 Nov; 119(11):1358-1366. PubMed ID: 30420613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 3. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.
    Lozano E; Asensio M; Perez-Silva L; Banales JM; Briz O; Marin JJG
    Hepatology; 2020 Sep; 72(3):949-964. PubMed ID: 31863486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
    Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
    Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.
    Ahn KS; O'Brien D; Kang YN; Mounajjed T; Kim YH; Kim TS; Kocher JA; Allotey LK; Borad MJ; Roberts LR; Kang KJ
    Hepatol Int; 2019 Jul; 13(4):490-500. PubMed ID: 31214875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
    Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models.
    Awasthi N; Darman L; Schwarz MA; Schwarz RE
    J Cell Mol Med; 2024 Sep; 28(17):e18585. PubMed ID: 39223878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
    Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
    Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
    [No Abstract]   [Full Text] [Related]  

  • 12. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
    Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.
    Tsukagoshi M; Araki K; Yokobori T; Altan B; Suzuki H; Kubo N; Watanabe A; Ishii N; Hosouchi Y; Nishiyama M; Shirabe K; Kuwano H
    Oncotarget; 2017 Jun; 8(26):42159-42172. PubMed ID: 28178675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity.
    Tomooka F; Kaji K; Nishimura N; Kubo T; Iwai S; Shibamoto A; Suzuki J; Kitagawa K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation.
    Huyen NT; Prachayasittikul V; Chan-On W
    J Hepatobiliary Pancreat Sci; 2016 Jul; 23(7):397-405. PubMed ID: 27107220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
    Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.